JCI - Citations to Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

Citations to this article

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

Alla Danilkovitch-Miagkova, Berton Zbar

Alla Danilkovitch-Miagkova, Berton Zbar

Published April 1, 2002
Citation Information: J Clin Invest. 2002;109(7):863-867. https://doi.org/10.1172/JCI15418.

View: Text | PDF

Total citations by year

Year:	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	Total
Citations:	2	4	3	3	4	3	2	8	9	6	10	8	7	7	7	5	8	2	3	3	5	1	1	2	113

Citation information

Citations to this article (113)

Title and authors	Publication	Year
Potential Anti-tumor Effects and Apoptosis-inducing Mechanisms of Saponins: A Review. Santos EEP, de Oliveira Andrade ML, Dos Santos Nascimento IJ, Cibulski SP, da Silva Alves H	Current topics in medicinal chemistry	2025
Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications Ji M, Ganesan S, Xia B, Huo Y	Cancers	2025
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network Poliaková Turan M, Riedo R, Medo M, Pozzato C, Friese-Hamim M, Koch JP, Coggins SA, Li Q, Kim B, Albers J, Aebersold DM, Zamboni N, Zimmer Y, Medová M	Cancer research communications	2024
Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment Yao S, Liu X, Feng Y, Li Y, Xiao X, Han Y, Xia S	International Journal of Molecular Sciences	2024
Exploring of miR-155-5p, miR-181b-5p, and miR-454-3p Expressions in Circulating Cell-Free RNA: Insights from Peripheral Blood of Uveal Malignant Melanoma Patients. Masoumeh H, Tunay D, Demet ÖA, Samuray T, Hülya Y	Biochemical genetics	2024
Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective Pezzicoli G, Musci V, Ciciriello F, Salonne F, Cafforio P, Lionetti N, Ragno A, Rizzo M	Therapeutic Advances in Medical Oncology	2024
An Observatory for the MET Oncogene: A Guide for Targeted Therapies Altintas DM, Comoglio PM	Cancers	2023
Decanoic Acid Exerts Its Anti-Tumor Effects via Targeting c-Met Signaling Cascades in Hepatocellular Carcinoma Model Yang MH, Lee M, Deivasigamani A, Le DD, Mohan CD, Hui KM, Sethi G, Ahn KS	Cancers	2023
Dual anticancer and antibacterial activity of fluorescent naphthoimidazolium salts. Tran DN, Hoang TTH, Nandanwar S, Ho VTTX, Pham VT, Vu HD, Nguyen XH, Nguyen HT, Nguyen TV, Nguyen TKV, Tran DL, Park M, Lee S, Pham TC	RSC Advances	2023
Oncosuppressive roles of decorin through regulation of multiple receptors and diverse signaling pathways. Xie C, Mondal DK, Ulas M, Neill T, Iozzo RV	American journal of physiology. Cell physiology	2022
c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549. Min J, Long C, Zhang L, Duan J, Fan H, Chu F, Li Z	Bioengineered	2022
Case Report: Gene Heterogeneity in the Recurrent and Metastatic Lesions of a Myxoid Chondrosarcoma Patient With Aggressive Transformation He X, Wang Y, Zou C, Zheng C, Luo Y, Zhou Y, Tu C	Frontiers in Genetics	2022
A selective small-molecule inhibitor of c-Met suppresses keloid fibroblast growth in vitro and in a mouse model MH Choi, J Kim, JH Ha, JU Park	Scientific Reports	2021
Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial. Lee CJ, Modave E, Boeckx B, Stacchiotti S, Rutkowski P, Blay JY, Debiec-Rychter M, Sciot R, Lambrechts D, Wozniak A, Schöffski P	Cancers	2021
Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models. Deng S, Solinas A, Calvisi DF	Frontiers in Oncology	2021
Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer Garza-Treviño EN, Martínez-Rodríguez HG, Delgado-González P, Solís-Coronado O, Ortíz-Lopez R, Soto-Domínguez A, Treviño VM, Padilla-Rivas GR, Islas-Cisneros JF, Quiroz-Reyes AG, Said-Fernández SL	Molecular medicine reports	2021
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis H Liang, M Wang	OncoTargets and therapy	2020
Genomic profiling in renal cell carcinoma N Dizman, EJ Philip, SK Pal	Nature Reviews Nephrology	2020
Spectrum of Mesenchymal–Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis J Li, K Hu, L Zhou, J Huang, S Zeng, Z Xu, Y Yan	Frontiers in Oncology	2020
Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma HW Chun, R Hong	Oncology Letters	2019
Selection and characterization of FcεRI phospho-ITAM specific antibodies N Velappan, A Mahajan, L Naranjo, P Velappan, N Andrews, N Tiee, S Chakraborti, C Hemez, T Gaiotto, B Wilson, A Bradbury	mAbs	2019
Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis JH Kim, HS Kim, BJ Kim	Journal of Cancer	2018
Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs CY Tu, FJ Cheng, CM Chen, SL Wang, YC Hsiao, CH Chen, TC Hsia, YH He, BW Wang, IS Hsieh, YL Yeh, CH Tang, YJ Chen, WC Huang	Molecular Oncology	2018
Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme G Tuncel, R Kalkan	Medical Oncology	2018
Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer O Miranda, M Farooqui, J Siegfried	Cancers	2018
Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6 BT Finicle, MU Ramirez, G Liu, EM Selwan, AN McCracken, J Yu, Y Joo, J Nguyen, K Ou, SG Roy, VD Mendoza, DV Corrales, AL Edinger	Journal of cell science	2018
Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis JH Kim, HJ Jang, HS Kim, BJ Kim, SH Park	Journal of Cancer	2018
The Role of PI3K in Met Driven Cancer: A Recap A Hervieu, S Kermorgant	Frontiers in Molecular Biosciences	2018
First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors VL Keedy, HJ Lenz, L Saltz, JG Whisenant, JD Berlin, LH Camacho	Investigational New Drugs	2018
Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review Z Han, Y Wu, K Wang, Y Xiao, Z Cheng, X Sun, B Shen	EJNMMI Research	2017
Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway H Taniguchi, T Yamada, S Takeuchi, S Arai, K Fukuda, S Sakamoto, M Kawada, H Yamaguchi, H Mukae, S Yano	Cancer Science	2017
Management of Atypical Renal Cell Carcinomas BC Liaw, R Mehrazin, C Baker, JP Sfakianos, CK Tsao	Current Treatment Options in Oncology	2017
PD-L1 and c-MET expression and survival in patients with small cell lung cancer L Miao, Y Lu, Y Xu, G Zhang, Z Huang, L Gong, Y Fan	Oncotarget	2017
MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review JH Kim, HS Kim, BJ Kim	Oncotarget	2017
Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review JH Kim, BJ Kim, HS Kim	Oncotarget	2017
Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review JH Kim, HS Kim, BJ Kim, HJ Jang, J Lee	Oncotarget	2017
Microtubule Depolymerization by Kinase Inhibitors: Unexpected Findings of Dual Inhibitors K Tanabe	International journal of molecular sciences	2017
Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review JH Kim, BJ Kim, HS Kim	Oncotarget	2017
MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis C Cataisson, AM Michalowski, K Shibuya, A Ryscavage, M Klosterman, L Wright, W Dubois, F Liu, A Zhuang, KB Rodrigues, S Hoover, J Dwyer, MR Simpson, G Merlino, SH Yuspa	Science signaling	2016
Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery O Zarei, S Benvenuti, F Ustun-Alkan, M Hamzeh-Mivehroud, S Dastmalchi	Journal of Cancer Research and Clinical Oncology	2016
Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer: Importance of Targeting c-MET and HGF Interaction Y Kwon, AK Godwin	Reproductive sciences (Thousand Oaks, Calif.)	2016
Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells K Kryeziu, C Pirker, B Englinger, S Schoonhoven, M Spitzwieser, T Mohr, W Körner, R Weinmüllner, K Tav, J Grillari, M Cichna-Markl, W Berger, P Heffeter	Oncotarget	2016
Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met: Norstictic Acid as Breast Cancer and c-Met Inhibitor HY Ebrahim, HE Elsayed, MM Mohyeldin, MR Akl, J Bhattacharjee, S Egbert, KA el Sayed	Phytotherapy Research	2016
Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer Sun CC, Li SJ, Zhang F, Pan JY, Wang L, Yang CL, Xi YY, Li DJ	Oncotarget	2016
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma L Gramantieri, A Granito, E Guidetti	Journal of Hepatocellular Carcinoma	2015
Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis H Hu, Y Liu, T Jiang	Tumor Biology	2015
Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30 E Vigna, C Chiriaco, S Cignetto, L Fontani, C Basilico, F Petronzelli, PM Comoglio	Molecular Oncology	2015
Differential expression of genes encoding proteins of the HGF/MET system in insulinomas CD Murat, PW da Rosa, MA Fortes, L Corrêa, MC Machado, EM Novak, SA Siqueira, MA Pereira, ML Corrêa-Giannella, D Giannella-Neto, RR Giorgi	Diabetology & metabolic syndrome	2015
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy H Kawakami, I Okamoto	Gastric Cancer	2015
Development of antibody-based c-Met inhibitors for targeted cancer therapy WK You, DH Lee, ES Sung, JH Ahn, S An, J Huh	ImmunoTargets and Therapy	2015
Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation C Sun, S Li, C Yang, R Xue, Y Xi, L Wang, S Wang, Q He, J Huang, S Xie, W Jiang, D Li	Oncotarget	2015
[Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing] Hongge Liang, Mengzhao Wang	Zhongguo fei ai za zhi = Chinese journal of lung cancer	2015
Functional consequence of the MET-T1010I polymorphism in breast cancer. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM	Oncotarget	2015
Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells. Lee JS, Oh E, Yoo JY, Choi KS, Yoon MJ, Yun CO	Oncotarget	2015
FOXC2 promotes colorectal cancer metastasis by directly targeting MET YM Cui, HL Jiao, YP Ye, CM Chen, JX Wang, N Tang, TT Li, J Lin, L Qi, P Wu, SY Wang, MR He, L Liang, XW Bian, WT Liao, YQ Ding	Oncogene	2014
Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression BS Lee, S Kang, KA Kim, YJ Song, KH Cheong, HY Cha, CH Kim	Cell Death and Disease	2014
Analysis of MET genetic aberrations in breast cancer patients at MD Anderson phase I unit DM Gagliato, DL Jardim, G Falchook, C Tang, R Zinner, JJ Wheler, F Janku, V Subbiah, SA Piha-Paul, S Fu, K Hess, S Roy-Chowdhuri, S Moulder, AM Gonzalez-Angulo, F Meric-Bernstam, DS Hong	Clinical Breast Cancer	2014
MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors DL Jardim, DM Gagliato, G Falchook, R Zinner, JJ Wheler, F Janku, V Subbiah, SA Piha-Paul, S Fu, N Tannir, P Corn, C Tang, K Hess, S Roy-Chowdhuri, R Kurzrock, F Meric-Bernstam, DS Hong	Clinical Genitourinary Cancer	2014
MicroRNA-1 in Cardiac Diseases and Cancers J Li, X Dong, Z Wang, J Wu	The Korean Journal of Physiology & Pharmacology	2014
MET and Small-Cell Lung Cancer F Gelsomino, G Rossi, M Tiseo	Cancers	2014
Targeting MET Amplification as a New Oncogenic Driver H Kawakami, I Okamoto, W Okamoto, J Tanizaki, K Nakagawa, K Nishio	Cancers	2014
Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models E Ciamporcero, KM Miles, R Adelaiye, S Ramakrishnan, L Shen, S Ku, S Pizzimenti, B Sennino, G Barrera, R Pili	Molecular cancer therapeutics	2014
Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells C He, J Ai, W Xing, Y Chen, H Zhang, M Huang, Y Hu, J Ding, M Geng	Acta Pharmacologica Sinica	2013
Critical Role of S1PR1 and Integrin β4 in HGF/c-Met-mediated Increases in Vascular Integrity Y Ephstein, PA Singleton, W Chen, L Wang, R Salgia, P Kanteti, SM Dudek, JG Garcia, JR Jacobson	The Journal of biological chemistry	2013
A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma ME Olanich, FG Barr	Expert Opinion on Therapeutic Targets	2013
Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety MW Welker, J Trojan	Cancer management and research	2013
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition R Katayama, A Aoyama, T Yamori, J Qi, T Oh-hara, Y Song, JA Engelman, N Fujita	Cancer research	2013
MET overexpression and gene amplification in NSCLC: a clinical perspective F Cappuzzo, L Landi, G Minuti, D'Incecco, Salvini	Lung Cancer: Targets and Therapy	2013
Interplay Between HGF/SF–Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy Natan S, Tsarfaty G, Horev J, Haklai R, Kloog Y, Tsarfaty I	Oncoscience	2013
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607 Y Dai, DW Siemann	BMC Cancer	2012
Rhabdomyosarcomas: an overview on the experimental animal models A Zanola, S Rossi, F Faggi, E Monti, A Fanzani	Journal of Cellular and Molecular Medicine	2012
Targeting the hepatocyte growth factor-cMET axis in cancer therapy GR Blumenschein, GB Mills, AM Gonzalez-Angulo	Journal of Clinical Oncology	2012
Frequency of MET and PIK3CA copy number elevation and correlation with outcome in early stage breast cancer AM Gonzalez-Angulo, H Chen, MS Karuturi, M Chavez-MacGregor, S Tsavachidis, F Meric-Bernstam, KA Do, GN Hortobagyi, PA Thompson, GB Mills, ML Bondy, GR Blumenschein	Cancer	2012
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation Y Dai, K Bae, C Pampo, DW Siemann	Clinical & Experimental Metastasis	2012
C-Met Inhibitor MK-8003 Radiosensitizes c-Met–Expressing Non–Small-Cell Lung Cancer Cells With Radiation-Induced c-Met–Expression: V Bhardwaj, Y Zhan, MA Cortez, KK Ang, D Molkentine, A Munshi, U Raju, R Komaki, JV Heymach, J Welsh	Journal of Thoracic Oncology	2012
Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer T Ach, K Zeitler, S Schwarz-Furlan, K Baader, A Agaimy, C Rohrmeier, J Zenk, M Gosau, TE Reichert, G Brockhoff, T Ettl	Virchows Archiv	2012
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines E Arriola, I Cañadas, M Arumí-Uría, M Dómine, JA Lopez-Vilariño, O Arpí, M Salido, S Menéndez, E Grande, FR Hirsch, S Serrano, B Bellosillo, F Rojo, A Rovira, J Albanell	British Journal of Cancer	2011
An overview of the c-MET signaling pathway SL Organ, MS Tsao, JS de Bono	Therapeutic advances in medical oncology	2011
Caveolins in rhabdomyosarcoma S Rossi, PL Poliani, C Missale, E Monti, A Fanzani	Journal of Cellular and Molecular Medicine	2011
Molecular Imaging for Guiding Oncologic Prognosis and Therapy in Esophageal Adenocarcinoma S Yentz, TD Wang	Hospital Practice	2011
Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib K Masago, Y Togashi, S Fujita, Y Sakamori, C Okuda, YH Kim, T Mio, M Mishima	Medical Oncology	2011
c-MET as a potential therapeutic target and biomarker in cancer JR Sierra, MS Tsao, JS de Bono	Therapeutic advances in medical oncology	2011
Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197 S Eathiraj, R Palma, E Volckova, M Hirschi, DS France, MA Ashwell, TC Chan	The Journal of biological chemistry	2011
C-MET as a new therapeutic target for the development of novel anticancer drugs I Cañadas, F Rojo, M Arumí-Uría, A Rovira, J Albanell, E Arriola	Clinical and Translational Oncology	2010
A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor F Schelter, J Kobuch, ML Moss, JD Becherer, PM Comoglio, C Boccaccio, A Krüger	The Journal of biological chemistry	2010
MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions F Grabellus, MJ Konik, K Worm, SY Sheu, JA van de Nes, S Bauer, W Paulus, R Egensperger, KW Schmid	Tumor Biology	2010
STAT5 Activation Is Critical for the Transformation Mediated by Myeloproliferative Disorder-associated JAK2 V617F Mutant M Funakoshi-Tago, K Tago, M Abe, Y Sonoda, T Kasahara	The Journal of biological chemistry	2010
TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation W Okamoto, I Okamoto, K Tanaka, E Hatashita, Y Yamada, K Kuwata, H Yamaguchi, T Arao, K Nishio, M Fukuoka, PA Jänne, K Nakagawa	Molecular cancer therapeutics	2010
Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene S Merlin, S Pietronave, D Locarno, G Valente, A Follenzi, M Prat	Cancer Science	2009
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells HE Crosswell, A Dasgupta, CS Alvarado, T Watt, JG Christensen, P De, DL Durden, HW Findley	BMC Cancer	2009
Decorin is a novel antagonistic ligand of the Met receptor S Goldoni, A Humphries, A Nyström, S Sattar, RT Owens, DJ McQuillan, K Ireton, RV Iozzo	The Journal of Cell Biology	2009
MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers P Ghadjar, W Blank-Liss, M Simcock, I Hegyi, KT Beer, H Moch, DM Aebersold, Y Zimmer	Clinical & Experimental Metastasis	2009
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells JW Welsh, D Mahadevan, R Ellsworth, L Cooke, D Bearss, B Stea	Radiation Oncology	2009
The Acute Lymphoblastic Leukemia-associated JAK2 L611S Mutant Induces Tumorigenesis in Nude Mice M Funakoshi-Tago, K Tago, K Sumi, M Abe, E Aizu-Yokota, T Oshio, Y Sonoda, T Kasahara	The Journal of biological chemistry	2009
MicroRNA-1/206 Targets c- Met and Inhibits Rhabdomyosarcoma Development D Yan, XD Dong, X Chen, L Wang, C Lu, J Wang, J Qu, LL Tu	The Journal of biological chemistry	2009
Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Wang S, Pashtan I, Tsutsumi S, Xu W, Neckers L	Cell cycle (Georgetown, Tex.)	2009
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer N Puri, R Salgia	Journal of carcinogenesis	2008
Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation PR Sheth, JL Hays, LA Elferink, SJ Watowich	Biochemistry	2008
Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling J Lackey, J Barnett, L Davidson, IH Batty, NR Leslie, CP Downes	Oncogene	2007
Diacylglycerol Kinase-α Mediates Hepatocyte Growth Factor-induced Epithelial Cell Scatter by Regulating Rac Activation and Membrane Ruffling F Chianale, S Cutrupi, E Rainero, G Baldanzi, PE Porporato, S Traini, N Filigheddu, VF Gnocchi, MM Santoro, O Parolini, WJ van Blitterswijk, F Sinigaglia, A Graziani, JS Gutkind	Molecular biology of the cell	2007
Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B	Pharmaceutical Research	2007
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer S Kanda, Y Miyata, H Kanetake	International Journal of Clinical Oncology	2006
P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin ME Reyes-Reyes, MD George, JD Roberts, SK Akiyama	Experimental Cell Research	2006
Inhibitory effect of c‐Met mutants on the formation of branching tubules by a porcine aortic endothelial cell line Maemura M, Yoshimoto A, Tsukada Y, Morishita Y, Miyazawa K, Tanaka T, Kitamura N	Cancer Science	2006
Co-Expression of Cox-2, C-Met and β-catenin in Cells Forming Invasive front of Gallbladder Cancer WS Moon, HS Park, H Lee, R Pai, AS Tarnawski, KR Kim, KY Jang	Cancer Research and Treatment	2005
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor TW Bauer, F Fan, W Liu, M Johnson, NU Parikh, GC Parry, J Callahan, AP Mazar, GE Gallick, LM Ellis	Annals of Surgery	2005
Hepatocyte growth factor promotes lymphatic vessel formation and function K Kajiya, S Hirakawa, B Ma, I Drinnenberg, M Detmar	The EMBO Journal	2005
Negative Feedback Regulation of Met-Dependent Invasive Growth by Notch MC Stella, L Trusolino, S Pennacchietti, PM Comoglio	Molecular and cellular biology	2005
Activation of c‐Met (hepatocyte growth factor receptor) in human gastric cancer tissue Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D, Kitamura N, Miyazawa K	Cancer Science	2005
Divergent functions of murine Pax3 and Pax7 in limb muscle development F Relaix, D Rocancourt, A Mansouri, M Buckingham	Genes & development	2004
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a N Schiering, S Knapp, M Marconi, MM Flocco, J Cui, R Perego, L Rusconi, C Cristiani	Proceedings of the National Academy of Sciences	2003
Invasive growth: from development to metastasis Paolo M. Comoglio, Livio Trusolino	Journal of Clinical Investigation	2002
Integrins in invasive growth Cord Brakebusch, Daniel Bouvard, Fabio Stanchi, Takao Sakai	Journal of Clinical Investigation	2002

Advertisement